MYD88 and lung cancer: who determined that the most likely etiology of ‘secondary CAD’ in a patient with lung cancer treated with pembrolizumab was a low-grade B-cell lymphoma with lymphoplasmacytic differentiation negative for the MYD88 mutation (42).